title: Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
abstract: BACKGROUND
  There is no standard treatment for patients with colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment. Here we aimed to retrospectively evaluate the efficacy and tolerability of raltitrexed in combination with oral 5-fluoropyrimidine (uracil tegafur-UFT) or mitomycin C as salvage therapy in mCRC patients.
  
  
  METHODS
  A total of 62 patients who had received raltitrexed combined with UFT or mitomycin C were identified between December 2008 and June 2013. They were given raltitrexed 2.6 mg/m2 (max 5 mg) i.v. on day 1 in combination with either oral UFT 500 mg/day on days 1-14 every 3 weeks (group A) or mitomycin C 6 mg/m2 i.v. on day every 3 weeks (group B).
  
  
  RESULTS
  Forty-two patients (67.7%) were in group A and 20 (32.2%) in group B. In 15 patients (24%) grade 3/4 toxicity was observed, resulting in dose reduction, and in 13 patients (20.9%) dose delay was necessary. The median progression free survival (PFS) was 3 months (95%CI 2.65-3.34) and median overall survival (OS) was 6 months (95%CI 2.09-9.90) in the whole group. Median PFS was 3 months (95%CI 2.60-3.39) in group A vs 3 months (95%CI 1.64-4.35) in group B (p=0.90). Median OS was 6 months (95%CI 2.47-9.53) in group A vs 12 months (95%CI 2.83-21.1) in group B (p=0.46).
  
  
  CONCLUSIONS
  The combination of raltitrexed with UFT or mitomycin C seem to be a salvage therapy option due to safety profile and moderate clinical activity in heavily-pretreated mCRC patients.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Erciyes University, Kayseri, Turkey E-mail : bozkurt.oktay8@gmail.com.
authors.forename: Oktay
authors.initials: O
authors.lastname: Bozkurt
authors.forename: Halit
authors.initials: H
authors.lastname: Karaca
authors.forename: Aydin
authors.initials: A
authors.lastname: Ciltas
authors.forename: M Ali
authors.initials: MA
authors.lastname: Kaplan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Alper
authors.initials: A
authors.lastname: Sevinc
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Tulay
authors.initials: T
authors.lastname: Eren
authors.forename: Hilmi
authors.initials: H
authors.lastname: Kodaz
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Isikdogan
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005493:Folic Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D005493:Folic Acid Antagonists; D011799:Quinazolines; D013876:Thiophenes; D005641:Tegafur; D016685:Mitomycin; C068874:raltitrexed